[go: up one dir, main page]

WO2003013522A1 - Preventives/remedies for cholinergic neuropathy - Google Patents

Preventives/remedies for cholinergic neuropathy Download PDF

Info

Publication number
WO2003013522A1
WO2003013522A1 PCT/JP2002/007960 JP0207960W WO03013522A1 WO 2003013522 A1 WO2003013522 A1 WO 2003013522A1 JP 0207960 W JP0207960 W JP 0207960W WO 03013522 A1 WO03013522 A1 WO 03013522A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
preventives
remedies
cholinergic
count
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/007960
Other languages
English (en)
French (fr)
Inventor
Ken Takashina
Tomoko Bessho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Priority to EP02755819A priority Critical patent/EP1415651A4/en
Priority to US10/486,051 priority patent/US20040235884A1/en
Priority to CA002456594A priority patent/CA2456594A1/en
Priority to JP2003518531A priority patent/JPWO2003013522A1/ja
Publication of WO2003013522A1 publication Critical patent/WO2003013522A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/JP2002/007960 2001-08-06 2002-08-05 Preventives/remedies for cholinergic neuropathy Ceased WO2003013522A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02755819A EP1415651A4 (en) 2001-08-06 2002-08-05 MEANS FOR THE PREVENTION AND TREATMENT OF CHOLINERGEN NEUROPATHY
US10/486,051 US20040235884A1 (en) 2001-08-06 2002-08-05 Preventives/remedies for cholinergic neuropathy
CA002456594A CA2456594A1 (en) 2001-08-06 2002-08-05 Preventives/remedies for cholinergic neuropathy
JP2003518531A JPWO2003013522A1 (ja) 2001-08-06 2002-08-05 コリン作動性神経障害予防・治療薬

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-238476 2001-08-06
JP2001238476 2001-08-06

Publications (1)

Publication Number Publication Date
WO2003013522A1 true WO2003013522A1 (en) 2003-02-20

Family

ID=19069376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007960 Ceased WO2003013522A1 (en) 2001-08-06 2002-08-05 Preventives/remedies for cholinergic neuropathy

Country Status (5)

Country Link
US (1) US20040235884A1 (ja)
EP (1) EP1415651A4 (ja)
JP (1) JPWO2003013522A1 (ja)
CA (1) CA2456594A1 (ja)
WO (1) WO2003013522A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス,インコーポレイティド 4−アシルアミノピリジン誘導体を含む組み合わせ

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03218361A (ja) * 1989-11-08 1991-09-25 Mitsubishi Kasei Corp 9―アシルアミノテトラヒドロアクリジン誘導体
JPH08104633A (ja) * 1994-10-07 1996-04-23 Mitsubishi Chem Corp コリン作動性神経系障害の治療および予防薬
WO2001016315A1 (fr) * 1999-08-27 2001-03-08 Japan Science And Technology Corporation Transporteur de choline a forte activite

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0282959A3 (en) * 1987-03-17 1989-05-31 Hoechst-Roussel Pharmaceuticals Incorporated Substituted 9-amino-tetrahydro-acridines and related compounds, a process for their preparation and their use as medicaments
CA2029497C (en) * 1989-11-08 2002-06-04 Kunihiro Ninomiya (Deceased) 4-acylaminopyridine derivative
HU213107B (en) * 1994-02-23 1997-02-28 Egyt Gyogyszervegyeszeti Gyar Process for producing acetic acid derivatives and pharmaceutical compositions containing them
JPH0892100A (ja) * 1994-09-21 1996-04-09 Mitsubishi Chem Corp 神経系障害の治療および予防薬
WO1996030372A1 (en) * 1995-03-24 1996-10-03 Japan Tobacco Inc. Diazabicyclo[3.3.1]nonane derivatives and intermediates thereof, medicinal use of the same, and processes for producing the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03218361A (ja) * 1989-11-08 1991-09-25 Mitsubishi Kasei Corp 9―アシルアミノテトラヒドロアクリジン誘導体
JPH08104633A (ja) * 1994-10-07 1996-04-23 Mitsubishi Chem Corp コリン作動性神経系障害の治療および予防薬
WO2001016315A1 (fr) * 1999-08-27 2001-03-08 Japan Science And Technology Corporation Transporteur de choline a forte activite

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1415651A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502722A (ja) * 2006-09-08 2010-01-28 ブレインセルス,インコーポレイティド 4−アシルアミノピリジン誘導体を含む組み合わせ

Also Published As

Publication number Publication date
EP1415651A1 (en) 2004-05-06
EP1415651A4 (en) 2005-11-09
CA2456594A1 (en) 2003-02-20
JPWO2003013522A1 (ja) 2004-12-02
US20040235884A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
WO2005046640A3 (en) Multi-site drug delivery platform
US20090202635A1 (en) Delivery System, Application, and Method
SG146638A1 (en) Pharmaceutical delivery system
ITRM930591A0 (it) Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
WO2004112711A3 (en) Oral extended-release composition
ATE509616T1 (de) Topische pharmazeutische und/oder cosmetische dosierungssysteme
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
TNSN00207A1 (en) Antidiabetic formulation and method
MXPA03006217A (es) Sistema de administracion espaciada de farmacos.
CA2386442A1 (en) Apparatus for administering aerosols
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
WO1989003673A1 (fr) Medicament comprenant l'association de polymyxine b, de tobramycine et d'amphotericine b administre par vaporisation
ES2139842T3 (es) Uso de la melatonina para tratar a pacientes que sufren drogodependencia.
CA2060560C (en) Method for insuring adequate intracellular glutathione in tissue
JP2005525329A5 (ja)
EP1643999B8 (en) Pyridoxamine for use in the treatment of diabetic nephropathy in type ii diabetes
EP1452176A4 (en) AGENTS FOR IMPROVING THE STATE OF RESISTANCE OF INSULIN
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
SE9301877D0 (sv) In situ gel for therapeutic use
CA2396209A1 (en) The use of mirtazapine for the treatment of sleep disorders
WO2003013522A1 (en) Preventives/remedies for cholinergic neuropathy
WO2002017952A3 (en) Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
Singer et al. Once-daily aminoglycoside therapy: potential ototoxicity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003518531

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2456594

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002755819

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10486051

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002755819

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2002755819

Country of ref document: EP